Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes

BACKGROUND: To assess the effects of proprotein convertase subtilisin/kexin type 9 inhibitor (evolocumab) on lipoprotein particles subfractions with Nuclear Magnetic Resonance spectroscopy in patients with acute coronary syndromes. METHODS: A total of 99 consecutive patients with ACS were enrolled a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tingting, Zhang, Yingyi, Cong, Hongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789487/
https://www.ncbi.nlm.nih.gov/pubmed/33413096
http://dx.doi.org/10.1186/s12872-020-01827-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789487/
https://www.ncbi.nlm.nih.gov/pubmed/33413096
http://dx.doi.org/10.1186/s12872-020-01827-0

Ejemplares similares